A Descriptive Study of HIV Patients Highly Adherent to Antiretroviral

AMIA Annu Symp Proc. 2021 Jan 25:2020:1295-1304. eCollection 2020.

Abstract

HIV medication adherence is a topic of major public health concern in the United States. Adherent patients may be less likely to experience treatment failure, AIDS presentations and extreme medical costs. We evaluate a cohort of highly adherent Medicare beneficiaries to establish if the out of pocket costs of HIV medications are an inherent barrier to adherence. We analyzed a 100% sample of Medicare Part-D prescription medications. The drug and out ofpocket costs for HIV and non-HIV medications of highly adherent cohort were extracted and analyzed. The average gross drug cost per beneficiary was $34,029for HIV medications and $11,439for non-HIV medications. Average out of pocket costs per beneficiary was $454for HIV medications and $129 for non-HIV medications. Out of pocket costs do not reasonably appear to be a barrier to adherence for Part-D beneficiaries.

Publication types

  • Research Support, N.I.H., Intramural

MeSH terms

  • Aged
  • Anti-Retroviral Agents / economics
  • Anti-Retroviral Agents / therapeutic use*
  • Cohort Studies
  • Female
  • HIV Infections / drug therapy*
  • Humans
  • Male
  • Medicare Part D / economics
  • Medication Adherence
  • Middle Aged
  • Prescription Drugs / economics
  • Prescription Drugs / therapeutic use
  • United States

Substances

  • Anti-Retroviral Agents
  • Prescription Drugs